Pfizer plans to begin testing its Covid-19 vaccine in children as young as 5, Pfizer Chairman and CEO Albert Bourla said Thursday. Bourla said that data on this population should be available by the end of the year.
Pfizer finished enrolling people ages 12 to 15 in its adolescent trial for the Pfizer/BioNTech Covid-19 vaccine in late January. Bourla said he hopes that data will be available in a couple of months.
“We are also planning to initiate pediatric studies from younger ages, from 5 all the way to 11, and I believe that we should have data about this population by the end of the year,” Bourla told NBC News’ Lester Holt.